This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adamis (ADMP) delivered earnings and revenue surprises of -33.33% and -1.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella receives a slew of regulatory approvals.
Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Masimo's (MASI) recent developments likely to show on second-quarter results.
What's in the Offing for DexCom's (DXCM) Earnings in Q2?
by Zacks Equity Research
Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.
Adamis Pharmaceuticals (ADMP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adamis (ADMP) delivered earnings and revenue surprises of -11.76% and -17.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
by Zacks Equity Research
Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.
Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adamis (ADMP) delivered earnings and revenue surprises of -40.00% and -28.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.
Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen
by Zacks Equity Research
Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.
Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adamis (ADMP) delivered earnings and revenue surprises of -70.59% and -5.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
by Zacks Equity Research
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
Adamis (ADMP) Surges Following Novartis Deal for Symjepi
by Zacks Equity Research
Shares of Adamis (ADMP) skyrocket after the company signs a commercialization deal with Novartis for Symjepi.
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
by Zacks Equity Research
Investors in Adamis Pharmaceuticals (ADMP) need to pay close attention to the stock based on moves in the options market lately.
What Falling Estimates & Price Mean for Adamis Pharmaceuticals (ADMP)
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Why Have Mylan's (MYL) Shares Lost 19.4% So Far This Year?
by Zacks Equity Research
Shares of Mylan N.V. (MYL) have lost almost 19.4% in the year so far given the competitive pressure.